PT - JOURNAL ARTICLE AU - Zhao, Yanteng AU - Wang, Zhijie AU - Yu, Qiuning AU - Liu, Xin AU - Liu, Xue AU - Dong, Shuling AU - Lv, Xianping AU - Zhang, Tiao AU - Zhou, Dihan AU - Yang, Qiankun TI - Discovering methylation markers and development of a sense-antisense and dual-MGB probe PCR assay in plasma for colorectal cancer early detection AID - 10.1101/2024.07.31.24311206 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.31.24311206 4099 - http://medrxiv.org/content/early/2024/08/02/2024.07.31.24311206.short 4100 - http://medrxiv.org/content/early/2024/08/02/2024.07.31.24311206.full AB - Screening for colorectal cancer (CRC) using plasma methylation is challenging due to the low abundance of cell-free DNA (cfDNA). Therefore, the development of signal amplification assays based on appropriate markers is essential to increase sensitivity. In this study, we employed an epigenome-wide approach for de novo identification differentially methylated CpGs (DMCs) common to CRC and adenoma using 17 public datasets. A sense-antisense and dual MGB probe (SADMP) assay was then developed. Subsequently, the biomarkers were validated in 712 plasma samples based on SADMP. A total of 2237 DMCs showed overlap between CRC and adenoma. Of these, 75 were hypomethylated in 30 other non-CRC cancers. Following LASSO regression, WBC validation and primer/probe design evaluation, NTMT1 and MAP3K14-AS1 were identified as the most informative candidate biomarkers. At preset template concentrations, the SADMP assay for NTMT1 or MAP3K14-AS1 could reduce the cycle threshold by 1. The NTMT1 and MAP3K14-AS1 dual-target SADMP assay demonstrated a sensitivity of 84.8% for CRC (stage I: 75.0%), a sensitivity of 32.0% for advanced adenomas (AA), and a specificity of 91.5% in controls. The dual-target assay showed high performance for CRC early detection in plasma, suggesting that it may serve as a promising noninvasive tool for CRC screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by science and technology project of Henan Province (232102310028)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of the First Affiliated Hospital of Zhengzhou University (approval number: 2022-KY-0631-002).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets (GSE77954, GSE101764, GSE131013, GSE164811, GSE193535, GSE129364, GSE139404, GSE107352, GSE75546, GSE77965, GSE199057, GSE68060, GSE48684, GSE40279 and GSE122126) supporting the conclusions of this article are available in the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi). The E-MTAB-6450 data is available in EMBL biostudies (https://www.ebi.ac.uk/biostudies/arrayexpress). The source code and intermediate data can be accessed from git-hub (https://github.com/amsinfor/CRC-methylation).